
## **Ron Handels**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11171290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
2	Is there equity in initial access to formal dementia care in Europe? The Andersen Model applied to the Actifcare cohort. International Journal of Geriatric Psychiatry, 2020, 35, 45-52.	2.7	13
3	Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia. Aging and Mental Health, 2019, 23, 53-59.	2.8	12
4	Needs and quality of life of people with middle-stage dementia and their family carers from the European Actifcare study. When informal care alone may not suffice. Aging and Mental Health, 2018, 22, 897-902.	2.8	57
5	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
6	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
7	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108

 $\frac{1}{2}$  Access to timely formal dementia care in Europe: protocol of the Actifcare (ACcess to Timely Formal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

9	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281.	3.1	75
10	Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design. Journal of Alzheimer's Disease, 2010, 20, 881-891.	2.6	130